Lexeo Therapeutics agrees to buy Mantle Therapeutics for up to $21.3 million
Bitget2026/09/22 11:03- Lexeo Therapeutics reached a definitive agreement to acquire Mantle Therapeutics, adding several frataxin-restoration programs targeting Friedreich ataxia neurology.
- Consideration totals USD 8.3 million upfront in cash and equity, with up to USD 13 million in milestone payments in cash and equity.
- Deal value could reach USD 21.3 million; closing is expected in the third quarter of 2026, subject to customary conditions.
- Acquired assets include a clinical-stage oral combination therapy, a preclinical CNS-penetrant small molecule, and TfR1-based brain-delivery biologics.
- Cash runway guidance remains into 2028; an IND for the next FA development candidate is targeted for 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
